Certain enzyme inhibitors may slow tumor formation within weeks and could lead to treatments that retard or prevent recurrences of cancers, researchers at UT Southwestern Medical Center at Dallas have discovered.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.